- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01350960
Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH
A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC5001 Administered to Healthy Subjects and Subjects With Familial Hypercholesterolemia (FH)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Leiden, Niederlande, 2333
- Centre for Huma Drug Research (CHDR)
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Healthy male or female subjects and subjects with heterozygous Familial Hypercholesterolemia
- Healthy male or female subjects, age 18 to 65 years, inclusive will be enrolled in Cohorts 1 through 4.
- In Cohort 5, male or female subjects with heterozygous Familial Hypercholesterolemia, confirmed through genetic testing, without a history of cardiovascular disease (e.g. coronary artery, peripheral artery or cerebrovascular disease), hypertension or diabetes mellitus age 18-45 years, inclusive, will be enrolled.
- BMI of 18-33 kg/m2
Screening hematology, clinical chemistries, coagulation and urinalysis consistent with overall good health and the following criteria are met:
- LDL ≥.3.24 mmol/L (≥ 100 mg/dL)
- Triglycerides (fasted) < 4.5 mmol/L (< 398 mg/dL)
- ALT within normal limits for healthy subjects and ALT < 2 x ULN for FH subjects
Exclusion Criteria:
Any uncontrolled or active major systemic disease including, but not limited to: cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological, psychiatric, or neoplastic disorder with metastatic potential
- History or presence of malignancy within the past year is an exclusion criterion. Subjects who have been successfully treated with no recurrence of basal cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled.
- Active acute or chronic infection, including, but not limited to: upper airway infection, urinary tract infection, and skin infection
- Use of prescription medication within 14 days prior to the planned first drug administration and throughout the study. For the FH subjects statin therapy (and other lipid lowering therapies) will be prohibited within 4 weeks prior to the first study drug administration.
- Use of non-prescription or over-the-counter medications is prohibited within 7 days prior to the planned first drug administration and throughout the study. This includes all vitamins, herbal supplements, or remedies. An exception can be made for medication or supplements that in the opinion of both the investigator and the Sponsor do not complicate or compromise the study or interfere with the study objectives.
- Positive results on the following Screening laboratory tests: urine or serum pregnancy test (women only), alcohol breath test, urine drugs of abuse, hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Placebo-Komparator: saline 0.9%
|
3 weekly SC injections
|
Experimental: Cohort 1
0.5 mg/kg in Healthy Subjects
|
3 weekly SC injections
|
Experimental: Cohort 2
1.5 mg/kg in Healthy subjects
|
3 weekly SC injections
|
Experimental: Cohort 3
5.0 mg/kg in Healthy subjects
|
3 weekly SC injections
|
Experimental: Cohort 4
10 mg/kg in Healthy subjects
|
3 weekly SC injections
|
Experimental: Cohort 5
TBD mg/kg in FH subjects
|
3 weekly SC injections
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Safety and Tolerability
Zeitfenster: Regularly over 78 days
|
Safety evaluation will assess adverse event (AE) profile, clinical laboratory safety tests, vital signs and ECG monitoring
|
Regularly over 78 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Peak Plasma Concentration (Cmax) of SPC5001
Zeitfenster: up to 78 days
|
up to 78 days
|
Lipid lowering effect
Zeitfenster: Through out the study
|
Through out the study
|
Area under the plasma concentration versus time curve (AUC) of SPC5001
Zeitfenster: up to 78 days
|
up to 78 days
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Koos Burggraaf, MD PhD, Centre for Human Drug Research (CHDR)
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- SPC5001-901
- EudraCT 2011-000489-36
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .